|
1
|
de Groot PM, Wu CC, Carter BW and Munden
RF: The epidemiology of lung cancer. Transl Lung Cancer Res.
7:220–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
4
|
Alsatari ES, Smith KR, Galappaththi SPL,
Turbat-Herrera EA and Dasgupta S: The current roadmap of lung
cancer biology, genomics and racial disparity. Int J Mol Sci.
26:38182025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao Y, Yang D, He J and Krasna MJ:
Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan Z, Liu H and Chen J: Lung cancer
stem-like cells and drug resistance. Zhongguo Fei Ai Za Zhi.
25:111–117. 2022.(In Chinese). PubMed/NCBI
|
|
7
|
Pradhan A, Pattnaik G, Das S, Acharya B
and Patra CN: Advancements in lung cancer: Molecular insights,
innovative therapies, and future prospects. Med Oncol. 42:3832025.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang Y, Bi Y, Zhou L, Zheng S, Jian T and
Chen J: Tanshinone IIA inhibits proliferation and migration by
downregulation of the PI3K/Akt pathway in small cell lung cancer
cells. BMC Complement Med Ther. 24:682024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Gong Y, Li L, Abdolmaleky HM and
Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer
in part via downregulation of Aurora A function. Mol Carcinog.
52:535–543. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Wang HJ, Xie W, Yao Y, Zhang YS
and Wang H: Cryptotanshinone inhibits lung tumorigenesis and
induces apoptosis in cancer cells in vitro and in vivo. Mol Med
Rep. 9:2447–2452. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin H, Sui H, Yu Y, Xie C, Shen Y, Cheng
L, Wang J, Yu Y, Xie C and Cui R: Dihydrotanshinone I potentiates
the anti-tumor activity of cisplatin by activating ROS-mediated ER
stress through targeting HSPD1 in lung cancer cells. Eur J
Pharmacol. 994:1773782025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang X, Jin L, Deng H, Wu D, Shen QK,
Quan ZS, Zhang CH and Guo HY: Research and development of natural
product tanshinone I: Pharmacology, total synthesis, and structure
modifications. Front Pharmacol. 13:9204112022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tian XH and Wu JH: Tanshinone derivatives:
A patent review (January 2006-September 2012). Expert Opin Ther
Pat. 23:19–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pang H, Wu L, Tang Y, Zhou G, Qu C and
Duan JA: Chemical analysis of the herbal medicine salviae
miltiorrhizae Radix et Rhizoma (Danshen). Molecules. 21:512016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Zou J, Cao D and Ma X:
Pharmacological basis of tanshinone and new insights into
tanshinone as a multitarget natural product for multifaceted
diseases. Biomed Pharmacother. 130:1105992020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sui H, Zhao J, Zhou L, Wen H, Deng W, Li
C, Ji Q, Liu X, Feng Y, Chai N, et al: Tanshinone IIA inhibits
β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in
normoxic and HIF-1α in hypoxic microenvironments in human
colorectal cancer. Cancer Lett. 403:86–97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tao S, Zheng Y, Lau A, Jaramillo MC, Chau
BT, Lantz RC, Wong PK, Wondrak GT and Zhang DD: Tanshinone I
Activates the Nrf2-dependent antioxidant response and protects
against As(III)-Induced lung inflammation in vitro and in vivo.
Antioxid Redox Signal. 19:1647–1661. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee DS, Lee SH, Noh JG and Hong SD:
Antibacterial activities of cryptotanshinone and dihydrotanshinone
I from a medicinal herb, Salvia miltiorrhiza Bunge. Biosci
Biotechnol Biochem. 63:2236–2239. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao H, Liu X, Sun W, Kang N, Liu Y, Yang
S, Xu QM, Wang C and Chen X: Total tanshinones exhibits
anti-inflammatory effects through blocking TLR4 dimerization via
the MyD88 pathway. Cell Death Dis. 8:e30042017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Shi DY, Liu SL and Zhong L:
Tanshinone IIA induces growth inhibition and apoptosis in gastric
cancer in vitro and in vivo. Oncol Rep. 27:523–528. 2012.PubMed/NCBI
|
|
21
|
Lee WY, Cheung CC, Liu KW, Fung KP, Wong
J, Lai PB and Yeung JH: Cytotoxic effects of tanshinones from
Salvia miltiorrhiza on doxorubicin-resistant human liver cancer
cells. J Nat Prod. 73:854–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang
J and Wang W: Potential anticancer activity of tanshinone IIA
against human breast cancer. Int J Cancer. 116:799–807. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue J, Jin X, Wan X, Yin X, Fang M, Liu T
and Zhao S: Effects and mechanism of tanshinone II A in
proliferation, apoptosis, and migration of human colon cancer
cells. Med Sci Monit. 25:4793–4800. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su CY, Ming QL, Rahman K, Han T and Qin
LP: Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and
pharmacology. Chin J Nat Med. 13:163–182. 2015.PubMed/NCBI
|
|
25
|
Hu T, Zou HX, Le SY, Wang YR, Qiao YM,
Yuan Y, Liu JC, Lai SQ and Huang H: Tanshinone IIA confers
protection against myocardial ischemia/reperfusion injury by
inhibiting ferroptosis and apoptosis via VDAC1. Int J Mol Med.
52:1092023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryu SY, Lee CO and Choi SU: In vitro
cytotoxicity of tanshinones from Salvia miltiorrhiza. Planta Med.
63:339–342. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu J, Zhang C, Shi X, Li J, Liu M, Jiang W
and Fang Z: Efficacy and safety of sodium tanshinone IIA sulfonate
injection on hypertensive nephropathy: A systematic review and
meta-analysis. Front Pharmacol. 10:15422019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia M, Wu Y, Zhu H and Duan W: Tanshinone
I induces ferroptosis in gastric cancer cells via the KDM4D/p53
pathway. Hum Exp Toxicol. 42:96032712312169632023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao J, Lou J, Mou Y, Li P, Wu J and Zhou
L: Diterpenoid tanshinones and phenolic acids from cultured hairy
roots of Salvia miltiorrhiza Bunge and their antimicrobial
activities. Molecules. 16:2259–2267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan Y, Kang S, Shao T, Xu L and Chen J:
Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by
suppressing the TGF-β/TSP-1 pathway and attenuating oxidative
stress. Cell Signal. 122:1113482024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu K, Feng C, Shao L, Mei L and Cao R:
Tanshinone IIA exhibits anti-inflammatory and antioxidative effects
in LPS-stimulated bovine endometrial epithelial cells by activating
the Nrf2 signaling pathway. Res Vet Sci. 136:220–226. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang P, Gu Y, Lu J, Song M, Hou W, Li P,
Sun Y, Wang J and Chen X: Endothelial TRPV4 channel mediates the
vasodilation induced by Tanshinone IIA. Chem Biol Interact.
402:1111812024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Zhong L, Mi S, Song N, Zhang W and
Zhong M: Tanshinone IIA prevents platelet activation and
down-regulates CD36 and MKK4/JNK2 signaling pathway. BMC Cardiovasc
Disord. 20:812020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Zhang Y, Feng X, Du M, Li S, Chang
X and Liu P: Tanshinone IIA alleviates atherosclerosis in LDLR(−/-)
mice by regulating efferocytosis of macrophages. Front Pharmacol.
14:12337092023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ding B, Lin C, Liu Q, He Y, Ruganzu JB,
Jin H, Peng X, Ji S, Ma Y and Yang W: Tanshinone IIA attenuates
neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in
vivo and in vitro. J Neuroinflammation. 17:3022020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qin C, Liu S, Zhou S, Xia X, Hu J, Yu Y
and Ma D: Tanshinone IIA promotes vascular normalization and boosts
Sorafenib's anti-hepatoma activity via modulating the PI3K-AKT
pathway. Front Pharmacol. 14:11895322023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feng F, Li N, Cheng P, Zhang H, Wang H,
Wang Y and Wang W: Tanshinone IIA attenuates silica-induced
pulmonary fibrosis via inhibition of TGF-β1-Smad signaling pathway.
Biomed Pharmacother. 121:1095862020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Z, Gao X, Jiao Y, Qiu Y, Wang A, Yu
M, Che F, Li S, Liu J, Li J, et al: Tanshinone IIA exerts
anti-inflammatory and immune-regulating effects on vulnerable
atherosclerotic plaque partially via the TLR4/MyD88/NF-κB signal
pathway. Front Pharmacol. 10:8502019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang Z, Gao W and Huang L: Tanshinones,
critical pharmacological components in Salvia miltiorrhiza. Front
Pharmacol. 10:2022019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang L, Song Y, Cheng Y and Liu X:
Orthogonal array design for the optimization of supercritical fluid
extraction of tanshinones from Danshen. J Sep Sci. 31:321–328.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang S, Liu Q, Luo H, Chen P, Wu X, Yang
M, Kong W and Guo W: UFLC-MS/MS analysis of four tanshinone
components in Salvia miltiorrhizae after ultrasound-assisted
extraction. J Chromatogr B Analyt Technol Biomed Life Sci.
1017–1018. 204–210. 2016.
|
|
42
|
Pan X, Niu G and Liu H: Microwave-assisted
extraction of tanshinones from Salvia miltiorrhiza bunge with
analysis by high-performance liquid chromatography. J Chromatogr A.
922:371–375. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Roth A, Zhao P, Soukup ST, Guigas C,
Stärke J, Kulling SE and Diel P: Chemical stability and bioactivity
of tanshinone I, tanshinone IIA, cryptotanshinone and
dihydrotanshinone in in vitro test systems. Toxicol Lett.
375:21–28. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang J, Qi H, Wang M, Wei Y and Liang H:
Enzymatically hydrolyzed sodium caseinate nanoparticles efficiently
enhancing the solubility, stability, and antioxidant and
anti-biofilm activities of hydrophobic Tanshinone IIA. J Mater Chem
B. 11:2440–2454. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hao H, Wang G, Cui N, Li J, Xie L and Ding
Z: Pharmacokinetics, absorption and tissue distribution of
tanshinone IIA solid dispersion. Planta Med. 72:1311–1317. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun J, Yang M, Han J, Wang B, Ma X, Xu M,
Liu P and Guo D: Profiling the metabolic difference of seven
tanshinones using high-performance liquid
chromatography/multi-stage mass spectrometry with data-dependent
acquisition. Rapid Commun Mass Spectrom. 21:2211–2226. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu C, Ye S, Sun H, Liu Y, Gao L, Shen C,
Chen S and Zeng S: PXR-mediated transcriptional activation of
CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact.
177:58–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ashour AA, Ramadan AA, Abdelmonsif DA and
El-Kamel AH: Enhanced oral bioavailability of Tanshinone IIA using
lipid nanocapsules: Formulation, in-vitro appraisal and
pharmacokinetics. Int J Pharm. 586:1195982020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen Z, Feng H, Peng C, Zhang Z, Yuan Q,
Gao H, Tang S and Xie C: Renoprotective effects of tanshinone IIA:
A literature review. Molecules. 28:19902023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang W, Li M, Wang L, Chen L and Goh BC:
Curcumin in cancer therapy: Exploring molecular mechanisms and
overcoming clinical challenges. Cancer Lett. 570:2163322023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Feitelson MA, Arzumanyan A, Kulathinal RJ,
Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML,
Nawroth R, Sanchez-Garcia I, et al: Sustained proliferation in
cancer: Mechanisms and novel therapeutic targets. Semin Cancer
Biol. 35 (Suppl):S25–S54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen W, Luo Y, Liu L, Zhou H, Xu B, Han X,
Shen T, Liu Z, Lu Y and Huang S: Cryptotanshinone inhibits cancer
cell proliferation by suppressing Mammalian target of
rapamycin-mediated cyclin D1 expression and Rb phosphorylation.
Cancer Prev Res (Phila). 3:1015–1025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang M, Zeng X, Li S, Sun Z, Yu J, Chen C,
Shen X, Pan W and Luo H: A novel tanshinone analog exerts
anti-cancer effects in prostate cancer by inducing cell apoptosis,
arresting cell cycle at G2 phase and blocking metastatic ability.
Int J Mol Sci. 20:44592019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rozengurt E: Autocrine loops, signal
transduction, and cell cycle abnormalities in the molecular biology
of lung cancer. Curr Opin Oncol. 11:116–122. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sun Y, Liu Y, Ma X and Hu H: The influence
of cell cycle regulation on chemotherapy. Int J Mol Sci.
22:69232021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang T, Zou J, Wu Q, Wang R, Yuan CL, Shu
J, Zhai BB, Huang XT, Liu NZ, Hua FY, et al: Tanshinone IIA
derivatives induced S-phase arrest through stabilizing c-myc
G-quadruplex DNA to regulate ROS-mediated PI3K/Akt/mTOR pathway.
Eur J Pharmacol. 912:1745862021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang B, Hao M, Li C and Luo KQ:
Acetyltanshinone IIA reduces the synthesis of cell cycle-related
proteins by degrading p70S6K and subsequently inhibits
drug-resistant lung cancer cell growth. Pharmacol Res.
179:1062092022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pahlavan Y, Mohammadi Nasr M, Dalir
Abdolahinia E, Pirdel Z, Razi Soofiyani S, Siahpoush S and Nejati
K: Prominent roles of microRNA-142 in cancer. Pathol Res Pract.
216:1532202020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jalava SE, Urbanucci A, Latonen L,
Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL
and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is
overexpressed in castration-resistant prostate cancer. Oncogene.
31:4460–4471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ma ZL, Zhang BJ, Wang DT, Li X, Wei JL,
Zhao BT, Jin Y, Li YL and Jin YX: Tanshinones suppress AURKA
through up-regulation of miR-32 expression in non-small cell lung
cancer. Oncotarget. 6:20111–20120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu X, Zou H, Zhao Y, Chen H, Liu T, Wu Z,
Yang C, Li Q and Li Y: Tanshinone inhibits NSCLC by downregulating
AURKA through Let-7a-5p. Front Genet. 11:8382020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang B, Ma Z, Li X, Zhang C, Shao Y, Liu
Z, Li Y and Jin Y: Tanshinones suppress non-small cell lung cancer
through up-regulating miR-137. Acta Biochim Biophys Sin (Shanghai).
48:768–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fuchs Y and Steller H: Programmed cell
death in animal development and disease. Cell. 147:742–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Fu L, Han B, Zhou Y, Ren J, Cao W, Patel
G, Kai G and Zhang J: The anticancer properties of tanshinones and
the pharmacological effects of their active ingredients. Front
Pharmacol. 11:1932020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vyas S, Zaganjor E and Haigis MC:
Mitochondria and cancer. Cell. 166:555–566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hung YC, Pan TL and Hu WL: Roles of
reactive oxygen species in anticancer therapy with salvia
miltiorrhiza bunge. Oxid Med Cell Longev. 2016:52932842016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
|
70
|
Ye YT, Zhong W, Sun P, Wang D, Wang C, Hu
LM and Qian JQ: Apoptosis induced by the methanol extract of Salvia
miltiorrhiza Bunge in non-small cell lung cancer through
PTEN-mediated inhibition of PI3K/Akt pathway. J Ethnopharmacol.
200:107–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liu F, Yu G, Wang G, Liu H, Wu X, Wang Q,
Liu M, Liao K, Wu M, Cheng X and Hao H: An NQO1-initiated and
p53-independent apoptotic pathway determines the anti-tumor effect
of tanshinone IIA against non-small cell lung cancer. PLoS One.
7:e421382012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Widden H and Placzek WJ: The multiple
mechanisms of MCL1 in the regulation of cell fate. Commun Biol.
4:10292021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Gao F, Li M, Liu W and Li W: Inhibition of
EGFR signaling and activation of mitochondrial apoptosis contribute
to tanshinone IIA-Mediated tumor suppression in non-small cell lung
cancer cells. Onco Targets Ther. 13:2757–2769. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Fu XL and Gao DS: Endoplasmic reticulum
proteins quality control and the unfolded protein response: The
regulative mechanism of organisms against stress injuries.
Biofactors. 40:569–585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wek RC and Cavener DR: Translational
control and the unfolded protein response. Antioxid Redox Signal.
9:2357–2371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kim EO, Kang SE, Im CR, Lee JH, Ahn KS,
Yang WM, Um JY, Lee SG and Yun M: Tanshinone IIA induces TRAIL
sensitization of human lung cancer cells through selective ER
stress induction. Int J Oncol. 48:2205–2212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang YZ, Lai HL, Huang C, Jiang ZB, Yan
HX, Wang XR, Xie C, Huang JM, Ren WK, Li JX, et al: Tanshinone IIA
induces ER stress and JNK activation to inhibit tumor growth and
enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Phytomedicine. 128:1554312024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W,
Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in
carcinogenesis. Mol Cancer. 17:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu D, Yuan R, Yang F and Zhang D: Effects
of tanshinones mediated by forkhead box O3a transcription factor on
the proliferation and apoptosis of lung cancer cells. Oncol Lett.
17:450–455. 2019.PubMed/NCBI
|
|
80
|
Steeg PS: Targeting metastasis. Nat Rev
Cancer. 16:201–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Perlikos F, Harrington KJ and Syrigos KN:
Key molecular mechanisms in lung cancer invasion and metastasis: A
comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jafri MA, Al-Qahtani MH and Shay JW: Role
of miRNAs in human cancer metastasis: Implications for therapeutic
intervention. Semin Cancer Biol. 44:117–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhu G, Li D, Wang X, Guo Q, Zhao Y, Hou W,
Li J and Zheng Q: Drug monomers from Salvia miltiorrhiza Bge.
promoting tight junction protein expression for therapeutic effects
on lung cancer. Sci Rep. 13:229282023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hansen TB, Jensen TI, Clausen BH, Bramsen
JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function
as efficient microRNA sponges. Nature. 495:384–388. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ye B, Qiao K, Zhao Q, Jiang Z, Hu N and
Wang F: Tanshinone I restrains osteosarcoma progression by
regulating circ_0000376/miR-432-5p/BCL2 axis. Mol Cell Biochem.
477:1–13. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sun F, Yang X, Song W, Yu N and Lin Q:
Tanshinone IIA (TSIIA) represses the progression of non-small cell
lung cancer by the circ_0020123/miR-1299/HMGB3 pathway. Mol Cell
Biochem. 478:1973–1986. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Liu L, Xu HX, Wang WQ, Wu CT, Chen T, Qin
Y, Liu C, Xu J, Long J, Zhang B, et al: Cavin-1 is essential for
the tumor-promoting effect of caveolin-1 and enhances its
prognostic potency in pancreatic cancer. Oncogene. 33:2728–2736.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang L, Jiang G and Li X: Diterpenoid
tanshinone attenuates the metastasis of non-small-cell lung cancer
(NSCLC) cells by inhibiting the cavin-1-mediated ERK/Smad2
signaling pathway. Anticancer Agents Med Chem. 23:1618–1625. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lee HT, Huang CH, Chen WC, Tsai CS, Chao
YL, Liu SH, Chen JH, Wu YY and Lee YJ: Transglutaminase 2 promotes
migration and invasion of lung cancer cells. Oncol Res.
26:1175–1182. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wang B, Gu X, Xiang BL, Zhao JQ, Zhang CH,
Huang PD and Zhang ZH: eEF-2K knockdown synergizes with STS
treatment to inhibit cell proliferation, migration, and invasion
via the TG2/ERK pathway in A549 cells. J Biochem Mol Toxicol.
36:e231582022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yousefi T, Mohammadi Jobani B, Taebi R and
Qujeq D: Innovating cancer treatment through cell cycle,
telomerase, angiogenesis, and metastasis. DNA Cell Biol.
43:438–451. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Chekhonin VP, Shein SA, Korchagina AA and
Gurina OI: VEGF in tumor progression and targeted therapy. Curr
Cancer Drug Targets. 13:423–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Tung YT, Chen HL, Lee CY, Chou YC, Lee PY,
Tsai HC, Lin YL and Chen CM: Active component of Danshen (Salvia
miltiorrhizaBunge), tanshinone I, attenuates lung tumorigenesis via
inhibitions of VEGF, cyclin A, and cyclin B expressions. Evid Based
Complement Alternat Med. 2013:3192472013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y,
Liu T, Wang D, Ge H and Mo SL: The antitumor effect of tanshinone
IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on
the human non-small cell lung cancer A549 cell line. Acta Pharm Sin
B. 5:554–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kontomanolis EN, Fasoulakis Z, Papamanolis
V, Koliantzaki S, Dimopoulos G and Kambas NJ: The impact of
microRNAs in breast cancer angiogenesis and progression. Microrna.
8:101–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang B, Zou F, Xin G, Xiang BL, Zhao JQ,
Yuan SF, Zhang XL and Zhang ZH: Sodium tanshinone IIA sulphate
inhibits angiogenesis in lung adenocarcinoma via mediation of
miR-874/eEF-2K/TG2 axis. Pharm Biol. 61:868–877. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Nasrollahzadeh E, Razi S, Keshavarz-Fathi
M, Mazzone M and Rezaei N: Pro-tumorigenic functions of macrophages
at the primary, invasive and metastatic tumor site. Cancer Immunol
Immunother. 69:1673–1697. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Liu L, Guo H, Song A, Huang J, Zhang Y,
Jin S, Li S, Zhang L, Yang C and Yang P: Progranulin inhibits
LPS-induced macrophage M1 polarization via NF-кB and MAPK pathways.
BMC Immunol. 21:322020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xu H, Guo NN, Zhu CY, Ye LY, Yan XY, Liu
YQ, Zhang ZY, Zhang G and Hussain L: Diterpenoid tanshinones can
inhibit lung cancer progression by improving the tumor
microenvironment and downregulation of NF-κB expression. ACS Omega.
9:7230–7238. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Liu S, Galat V, Galat Y, Lee YKA,
Wainwright D and Wu J: NK cell-based cancer immunotherapy: from
basic biology to clinical development. J Hematol Oncol. 14:72021.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Sun Y, Gong C, Ni Z, Hu D, Ng W, Zhu X,
Wang L, Si G, Yan X, Zhao C, et al: Tanshinone IIA enhances
susceptibility of non-small cell lung cancer cells to NK
cell-mediated lysis by up-regulating ULBP1 and DR5. J Leukoc Biol.
110:315–325. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Park JH, Pyun WY and Park HW: Cancer
metabolism: Phenotype, signaling and therapeutic targets. Cells.
9:23082020. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells.
FEBS J. 274:1393–1418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jin Z, Yun L and Cheng P: Tanshinone I
reprograms glycolysis metabolism to regulate histone H3 lysine 18
lactylation (H3K18la) and inhibits cancer cell growth in ovarian
cancer. Int J Biol Macromol. 291:1390722025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Qi H, Chen Z, Qin Y, Wang X, Zhang Z and
Li Y: Tanshinone IIA inhibits cell growth by suppressing
SIX1-induced aerobic glycolysis in non-small cell lung cancer
cells. Oncol Lett. 23:1842022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cao Y: Adipocyte and lipid metabolism in
cancer drug resistance. J Clin Invest. 129:3006–3017. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Cheng C, Geng F, Cheng X and Guo D: Lipid
metabolism reprogramming and its potential targets in cancer.
Cancer Commun (Lond). 38:272018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cao L, Qin Z, Yu T, Bai X, Jiang S, Wang
D, Ning F, Huang M and Jin J: Tanshinone IIA acts as a regulator of
lipogenesis to overcome osimertinib acquired resistance in lung
cancer. Biochem Pharmacol. 224:1162072024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang L, Xu C, Huang J, Jiang S, Qin Z,
Cao L, Tan G, Zhao Z, Huang M and Jin J: Tanshinone IIA reverses
gefitinib resistance in EGFR-mutant lung cancer via inhibition of
SREBP1-mediated lipogenesis. Phytother Res. 38:1574–1588. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zheng X, Song X, Zhu G, Pan D, Li H, Hu J,
Xiao K, Gong Q, Gu Z, Luo K and Li W: Nanomedicine combats drug
resistance in lung cancer. Adv Mater. 36:e23089772024. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Xi Z, Dai R, Ze Y, Jiang X, Liu M and Xu
H: Traditional Chinese medicine in lung cancer treatment. Mol
Cancer. 24:572025. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Fennell DA, Summers Y, Cadranel J, Benepal
T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C and Ferry
D: Cisplatin in the modern era: The backbone of first-line
chemotherapy for non-small cell lung cancer. Cancer Treat Rev.
44:42–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Liao XZ, Gao Y, Huang S, Chen ZZ, Sun LL,
Liu JH, Chen HR, Yu L, Zhang JX and Lin LZ: Tanshinone IIA combined
with cisplatin synergistically inhibits non-small-cell lung cancer
in vitro and in vivo via down-regulating the phosphatidylinositol
3-kinase/Akt signalling pathway. Phytother Res. 33:2298–2309. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Rahman AF, Korashy HM and Kassem MG:
Gefitinib. Profiles Drug Subst Excip Relat Methodol. 39:239–264.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Laface C, Maselli FM, Santoro AN, Iaia ML,
Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M and Fedele
P: The resistance to EGFR-TKIs in non-small cell lung cancer: From
molecular mechanisms to clinical application of new therapeutic
strategies. Pharmaceutics. 15:16042023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang R, Luo Z, Zhang H and Wang T:
Tanshinone IIA reverses gefitinib-resistance in human
non-small-cell lung cancer via regulation Of VEGFR/Akt pathway.
Onco Targets Ther. 12:9355–9365. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chen F, Xiang W and Qiang G: Tanshinone
IIA affects the proliferation of A549/Tax by affecting the
expression of MMP7 through the PI3K-AKT-mTOR signaling pathway.
Discov Oncol. 16:3692025. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhao J, Lin E, Cai C, Zhang M, Li D, Cai
S, Zeng G, Yin Z, Wang B, Li P, et al: Combined treatment of
tanshinone i and epirubicin revealed enhanced inhibition of
hepatocellular carcinoma by targeting PI3K/AKT/HIF-1α. Drug Des
Devel Ther. 16:3197–3213. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ge T, Li H, Xiang P, Yang D, Zhou J and
Zhang Y: Tanshinone IIA induces ferroptosis in colorectal cancer
cells through the suppression of SLC7A11 expression via the
PI3K/AKT/mTOR pathway. Eur J Med Res. 30:5762025. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cheng CY and Su CC: Tanshinone IIA may
inhibit the growth of small cell lung cancer H146 cells by
up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial
membrane potential. Mol Med Rep. 3:645–650. 2010.PubMed/NCBI
|
|
125
|
Chien SY, Kuo SJ, Chen YL, Chen DR, Cheng
CY and Su CC: Tanshinone IIA inhibits human hepatocellular
carcinoma J5 cell growth by increasing Bax and caspase 3 and
decreasing CD31 expression in vivo. Mol Med Rep. 5:282–286.
2012.PubMed/NCBI
|
|
126
|
Liu J, Zhang C, Liu S, Wang X, Wu X and
Hao J: Tanshinone IIA promotes apoptosis by downregulating BCL2 and
upregulating TP53 in triple-negative breast cancer. Naunyn
Schmiedebergs Arch Pharmacol. 396:365–374. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Gong Y, Li Y, Abdolmaleky HM, Li L and
Zhou JR: Tanshinones inhibit the growth of breast cancer cells
through epigenetic modification of Aurora A expression and
function. PLoS One. 7:e336562012. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lu M, Wang C and Wang J: Tanshinone I
induces human colorectal cancer cell apoptosis: The potential roles
of Aurora A-p53 and survivin-mediated signaling pathways. Int J
Oncol. 49:603–610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Ren X, Wang C, Xie B, Hu L, Chai H, Ding
L, Tang L, Xia Y and Dou X: Tanshinone IIA induced cell death via
miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular
carcinoma cells. Eur J Pharmacol. 796:233–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sharma R: Mapping of global, regional and
national incidence, mortality and mortality-to-incidence ratio of
lung cancer in 2020 and 2050. Int J Clin Oncol. 27:665–675. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Smolarz B, Łukasiewicz H, Samulak D,
Piekarska E, Kołaciński R and Romanowicz H: Lung
cancer-epidemiology, pathogenesis, treatment and molecular aspect
(Review of Literature). Int J Mol Sci. 26:20492025. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sharma A, Shambhwani D, Pandey S, Singh J,
Lalhlenmawia H, Kumarasamy M, Singh SK, Chellappan DK, Gupta G,
Prasher P, et al: Advances in lung cancer treatment using
nanomedicines. ACS Omega. 8:10–41. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Lee WD, Liang YJ and Chen BH: Effects of
tanshinone nanoemulsion and extract on inhibition of lung cancer
cells A549. Nanotechnology. 27:4951012016. View Article : Google Scholar : PubMed/NCBI
|
